Solventum Co. (NYSE:SOLV) Stock Holdings Reduced by Nuance Investments LLC

Nuance Investments LLC lessened its stake in shares of Solventum Co. (NYSE:SOLV) by 17.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,356,217 shares of the company’s stock after selling 283,136 shares during the quarter. Solventum makes up about 3.6% of Nuance Investments LLC’s portfolio, making the stock its 9th biggest position. Nuance Investments LLC’s holdings in Solventum were worth $89,592,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Worldquant Millennium Advisors LLC boosted its stake in Solventum by 373.6% in the third quarter. Worldquant Millennium Advisors LLC now owns 47,665 shares of the company’s stock valued at $3,323,000 after acquiring an additional 37,600 shares in the last quarter. Harbor Capital Advisors Inc. lifted its holdings in shares of Solventum by 24.8% during the 4th quarter. Harbor Capital Advisors Inc. now owns 46,965 shares of the company’s stock valued at $3,103,000 after purchasing an additional 9,333 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Solventum by 37.4% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 117,853 shares of the company’s stock worth $8,217,000 after purchasing an additional 32,051 shares in the last quarter. State Street Corp grew its stake in Solventum by 3.1% during the 3rd quarter. State Street Corp now owns 6,107,550 shares of the company’s stock worth $425,818,000 after buying an additional 185,938 shares during the last quarter. Finally, Forsta AP Fonden acquired a new position in Solventum during the 4th quarter valued at about $1,876,000.

Solventum Price Performance

NYSE:SOLV opened at $74.87 on Wednesday. The firm’s fifty day moving average is $75.38 and its two-hundred day moving average is $71.73. The firm has a market cap of $12.95 billion and a price-to-earnings ratio of 27.23. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. Solventum Co. has a one year low of $47.16 and a one year high of $85.92.

Analyst Ratings Changes

Several equities research analysts have weighed in on SOLV shares. Mizuho raised their price target on Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a report on Monday, March 3rd. The Goldman Sachs Group lifted their target price on shares of Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a research note on Monday, March 3rd. Piper Sandler upped their price target on shares of Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a research note on Friday, February 28th. Morgan Stanley lifted their price objective on shares of Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 5th. Finally, Wells Fargo & Company boosted their price objective on shares of Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $79.86.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.